Compares two hepatitis B medicines, tenofovir alafenamide and entecavir, in chronic infection
Compares tenofovir alafenamide with entecavir in adults with chronic hepatitis B.
Plain-language title generated from the registry record
Registry title: Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B
Key facts
- Where
- Taichung, TaiwanSee the site
- Phase
- Phase 4
Where in Taiwan
- Taichung Veterans General HospitalTaichung, TaiwanTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Taichung Veterans General Hospital
- Trial code
- NCT03933384
- Record updated
- 14 May 2026
- Original description
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.Read full original descriptionShow less
Tenofovir Alafenamide Versus Entecavir for the Treatment of Chronic Hepatitis B: An Open Label, Randomized Controlled Trial
To compare the efficacy and renal safety of tenofovir alafenamide (TAF) versus entecavir (ETV) in the chronic hepatitis B patients.
Inclusion: Patients more than 20 years old; Chronic hepatitis B patients; Patients who were indicated for hepatitis B virus antiviral therapy.
Exclusion: Prior use of nucleot(s)ide analogues for chronic hepatitis B; Prior use of interferon for chronic hepatitis B within six months; Concurrent other uncontrolled malignancy; Decompensated liver disease (Child-Pugh B \&C); End stage renal disease (eGRF < 15 ml/min/1.73m2); Known history of human immunodeficiency virus or hepatitis C virus co-infection; Women in pregnancy or lactation; Cannot conform to the study protocol of this study.